Français
ItalianoBond GSK PLC 3.125% ( USG4164DAA66 ) in USD
| Issuer | GSK PLC | ||||||||||||||
| Market price | 96.55 % ▼ | ||||||||||||||
| Country |  United Kingdom
|
||||||||||||||
| ISIN code |
 USG4164DAA66 ( in USD )
|
||||||||||||||
| Interest rate | 3.125% per year ( payment 2 times a year) | ||||||||||||||
| Maturity | 24/03/2025 - Bond has expired | ||||||||||||||
|
Prospectus brochure in PDF format |
|||||||||||||||
| Minimal amount | 250 000 USD | ||||||||||||||
| Total amount | 1 750 000 000 USD | ||||||||||||||
| Cusip | G4164DAA6 | ||||||||||||||
| Standard & Poor's ( S&P ) rating | BBB+ ( Lower medium grade - Investment-grade ) | ||||||||||||||
| Detailed description |
GSK PLC is a British multinational pharmaceutical and biopharmaceutical company headquartered in Brentford, UK, focused on research and development, manufacturing, and marketing of pharmaceuticals, vaccines, and consumer healthcare products globally. The Bond issued by GSK PLC ( United Kingdom ) , in USD, with the ISIN code USG4164DAA66, pays a coupon of 3.125% per year. The coupons are paid 2 times per year and the Bond maturity is 24/03/2025 The Bond issued by GSK PLC ( United Kingdom ) , in USD, with the ISIN code USG4164DAA66, was rated BBB+ ( Lower medium grade - Investment-grade ) by Standard & Poor's ( S&P ) credit rating agency. |
||||||||||||||
| |||||||||||||||